Cargando…

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety

INTRODUCTION: The inhibition of the calcitonin gene-related peptide (CGRP) pathway has attracted interest in pharmacological research on migraine. Atogepant is a potent, selective, orally available antagonist of the CGRP receptor approved as a preventive treatment of episodic migraine. This systemat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lattanzi, Simona, Trinka, Eugen, Altamura, Claudia, Del Giovane, Cinzia, Silvestrini, Mauro, Brigo, Francesco, Vernieri, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338214/ https://www.ncbi.nlm.nih.gov/pubmed/35705886 http://dx.doi.org/10.1007/s40120-022-00370-8

Ejemplares similares

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis
por: Lattanzi, Simona, et al.
Publicado: (2020)

Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis
por: Lattanzi, Simona, et al.
Publicado: (2022)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Lattanzi, Simona, et al.
Publicado: (2023)

Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis
por: Tabaee Damavandi, Payam, et al.
Publicado: (2023)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
por: Lattanzi, Simona, et al.
Publicado: (2021)

Latency of poststroke epilepsy can predict drug resistance
por: Lattanzi, Simona, et al.
Publicado: (2022)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Blood pressure variability and stroke: A risk marker of outcome and target for intervention
por: Lattanzi, Simona, et al.
Publicado: (2020)

Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy
por: Lattanzi, Simona, et al.
Publicado: (2018)

Individualized Prediction of Drug Resistance in People with Post-Stroke Epilepsy: A Retrospective Study
por: Lattanzi, Simona, et al.
Publicado: (2023)

Cortical Laminar Necrosis and Migrainous Stroke
por: Lattanzi, Simona, et al.
Publicado: (2019)

Clinical phenotypes within nonconvulsive status epilepticus
por: Lattanzi, Simona, et al.
Publicado: (2021)

Status epilepticus with prominent motor symptoms clusters into distinct electroclinical phenotypes
por: Lattanzi, Simona, et al.
Publicado: (2021)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures
por: Trinka, Eugen, et al.
Publicado: (2021)

Right-to-left shunts and hormonal therapy influence cerebral vasomotor reactivity in patients with migraine with aura
por: Altamura, Claudia, et al.
Publicado: (2019)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice
por: Paolucci, Matteo, et al.
Publicado: (2015)

Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study
por: Altamura, Claudia, et al.
Publicado: (2023)

Efficacy and Safety of Intravenous Valproate for Status Epilepticus: A Systematic Review
por: Trinka, Eugen, et al.
Publicado: (2014)

Commentary: Enhanced Hemodynamic and Clinical Response to αCGRP in Migraine Patients—A TCD Study
por: Altamura, Claudia, et al.
Publicado: (2021)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies
por: Lattanzi, Simona, et al.
Publicado: (2021)

Stroke territory and atherosclerosis in ischemic stroke patients with a history of migraine with aura
por: Altamura, Claudia, et al.
Publicado: (2023)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

The Role of Endothelial Dysfunction in the Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review
por: Paolucci, Matteo, et al.
Publicado: (2021)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Acute Symptomatic Seizures Caused by Electrolyte Disturbances
por: Nardone, Raffaele, et al.
Publicado: (2016)

The Healthy Eating Plate Advice for Migraine Prevention: An Interventional Study
por: Altamura, Claudia, et al.
Publicado: (2020)

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020)

Pharmacotherapy for Status Epilepticus
por: Trinka, Eugen, et al.
Publicado: (2015)

Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide
por: Nucera, Bruna, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_holuuivgo7qplrgggahl2ddkuq